お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
890224

競合企業の分析:がん免疫 & その他の疾患向け二重特異性抗体

Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases

出版日: | 発行: La Merie Publishing | ページ情報: 英文 125 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=108.90円
競合企業の分析:がん免疫 & その他の疾患向け二重特異性抗体
出版日: 2019年06月30日
発行: La Merie Publishing
ページ情報: 英文 125 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、がん、炎症性・自己免疫性疾患、および心臓代謝性・感染性・神経性・眼科疾患向けの二重特異性治療用抗体について調査し、各抗体の製造技術、現在のR&D情勢、競合企業のプロジェクトなどを分析しています。

第1章 T細胞リダイレクティング二重特異性抗体

  • BCMA標的
  • CD20標的
  • CD19標的
  • CD33標的
  • CD123標的
  • PSMA標的
  • Her2標的
  • メソテリン標的
  • CD38標的
  • EGF-R標的
  • DLL3 、ほか

第2章 二重特異性ナチュラルキラー (NK) 細胞リダイレクティング抗体

第3章 二重特異性T細胞エンゲージング、条件付き共刺激抗体

第4章 二重特異性がん免疫抗体

第5章 二重特異性腫瘍関連抗原 (TAA):抗体を標的にした成長要因

  • Her2標的
  • VEGF標的
  • その他TAA標的

第6章 癌以外の症状に対する二重特異性抗体

  • 炎症性・自己免疫性疾患
  • 心臓代謝性疾患
  • 眼科疾患
  • 神経性疾患
  • 感染症
  • 標的化遺伝子導入
目次
Product Code: LMCA0176

Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases

This Competitive Intelligence report about Bispecific Antibodies for Immuno-Oncology & Other Diseases evaluates the landscape of investigational bispecific therapeutic antibodies for treatment of cancer, inflammatory & autoimmune diseaseas as well as cardiometabolic, infectious, neurologic and ophthalmic diseases as of June 2019.

At present, only two bispecific therapeutic monoclonal antibodies are on the market, one for leukemia and one for hemophilia. La Merie Publishing conducted a search for bispecific monoclonal antibodies (and some multimeric proteins) in R&D. The search identified 271 unique bispecific antibody-based constructs in active R&D (excluding discontinued developments of bispecifics). Of the 110 clinical stage bispecific antibodies, 50% are used for redirection of T-cells to a tumor target. More than 85% of the clinical stage bispecific molecules are in development for treatment of cancer. The combination of immune checkpoint inhibitor and/or activator targets is a strongly emerging use of the bispecific antibody technology. The traditonal application of bispecifics for targeting two tumor-associated antigens (or epitopes) and/or growth factors is a field with strong clinical activities, but the non-clinical pipeline is relatively empty compared with immuno-oncology bispecifics (11 vs 48 projects).

The report highlights the use of bispecific antibody technology for generation of

  • T-Cell Redirecting Bispecific Antibodies
  • Bispecific Natural Killer (NK) Cell Redirecting Antibodies
  • Bispecific T-Cell Engaging, Conditional Costimulatory Antibodies
  • Bispecific Immuno-Oncology Antibodies
  • Bispecific Tumor Associated Antigen (TAA) / Growth Factor Targeted Antibodies
  • Bispecific Antibodies for Non-Cancer Indications

The report includes a compilation of currently active projects in research and development of bispecific therapeutic antibodies in cancer and non-cancer indications. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.

Table of Contents

1) T-Cell Redirecting Bispecific Antibodies

  • Targeting BCMA
  • Targeting CD20
  • Targeting CD19
  • Targeting CD33
  • Targeting CD123
  • argeting PSMA
  • Targeting Her2
  • Targeting Mesothelin
  • Targeting CD38
  • Targeting EGF-R
  • Targeting DLL3
  • Targeting Various Other Cancer Surface Antigens
  • Targeting Not Disclosed Tumor Associated Antigens
  • Targeting (Intracellular) peptide/MHC Antigens
  • Novel Bispecific T-Cell Redirecting Antibody Constructs
  • Bispecific T-Cell Redirecting Antibodies for Infectious & Other Diseases

2) Bispecific Natural Killer (NK) Cell Redirecting Antibodies

3) Bispecific T-Cell Engaging, Conditional Costimulatory Antibodies

  • Bispecific, Tumor-Targeted, Conditional 4-1BB Costimulatory Antibodies
  • Bispecific, Tumor-Targeted, Conditional CD40 Costimulatory Antibodies
  • Bispecific, Tumor-Targeted, Conditional CD28 or OX40 Costimulatory Antibodies
  • Bispecific, Dual Costimulatory Antibodies

4) Bispecific Immuno-Oncology Antibodies

  • Bispecific, Tumor-Targeted Checkpoint Inhibitor Antibodies
  • Bispecific Checkpoint Inhibitor & Costimulator Antibodies
  • Bispecific CD47 Tumor Microenvironment (TME) Targeted Antibodies
  • Other Bispecific, Tumor Microenvironment (TME) Targeted Antibodies
  • Bispecific, Dual PD-1 & PD-L1 Checkpoint Inhibitor Antibodies
  • Bispecific, Dual PD-1/PD-L1 & CTLA-4 Checkpoint Inhibitor Antibodies
  • Bispecific, Dual PD-1 & LAG-3 Checkpoint Inhibitor Antibodies
  • Bispecific, Dual PD-L1/CTLA-4 & LAG-3 Checkpoint Inhibitor Antibodies
  • Bispecific, PD-1/PD-L1/CTLA-4 & TIM-3 or GITR Checkpoint Inhibitor Antibodies
  • Bispecific, Not Specified Immuno-Oncology Antibodies

5) Bispecific Tumor Associated Antigen (TAA) / Growth Factor Targeted Antibodies

  • Bispecific Her2-Targeted Antibodies
  • Bispecific VEGF-Targeted Antibodies
  • Other Bispecific TAA-Targeted Antibodies

6) Bispecific Antibodies for Non-Cancer Indications

  • Bispecific Inflammatory & Autoimmune Disease Antibodies
  • Bispecific Cardiometabolic Antibodies
  • Bispecific Ophthalmic Disease Antibodies
  • Bispecific Neurologic Disease Antibodies
  • Bispecific Infectious Disease Antibodies
  • Bispecific Antibodies For Targeted Delivery
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.